Human papillomavirus and Epstein Barr virus in prostate cancer: Koilocytes indicate potential oncogenic influences of human papillomavirus in prostate cancer

Whitaker, Noel J.; Glenn, Wendy K.; Sahrudin, Arisha; Orde, Matthew M; Delprado, Warick; Lawson, James S.

doi:10.1002/pros.22562

Cited by 84 publications

(99 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…These studies were published between 1990 and 2015 and comprised 971 PCa cases in total. The majority of the studies originated from Asia (n=8) (38,40,(43)(44)(45)48,51,56), Europe (n=7) (22,39,42,47,50,53,55) and North America (n=5) (23,49,52,54,57), and the remaining studies originated from South America (n=1) (46) and Oceania (n=2) (6,41 Table I. Characteristics of studies included in the meta-analysis.…”

Section: Resultsmentioning

confidence: 99%

Association between human papillomavirus and prostate cancer: A meta-analysis

et al. 2017

View full text Add to dashboard Cite

Abstract. Observational studies have suggested an association between human papillomavirus (HPV) infection and the risk of prostate cancer (PCa). However, the association between HPV infection and the risk of PCa remains unclear. The aim of the present meta-analysis study was to investigate whether HPV serves a role in increasing the risk of PCa. Relevant previous studies up to May 2015 were searched in PubMed, Web of Science, Cochrane library, Chinese National Knowledge Infrastructure, China Wan Fang database and China Biomedical Literature Database. A random-effects model or fixed-effects model was employed to determine odds ratios (ORs) with 95% confidence intervals (CIs), when appropriate. Heterogeneity was evaluated using Q and I 2 statistical analysis. A total of 24 case-control studies involving 971 patients and 1,085 controls were investigated to estimate the association between HPV infection and PCa risk. The pooled estimate for OR was 2.27 (95% CI, 1.40-3.69). Stratified pooled analyses were subsequently performed according to the HPV detection methods, geographical regions, publication years and types of tissue. Sensitivity analysis based on various exclusion criteria maintained the significance with respect to PCa individually. Little evidence of publication bias was observed. The meta-analysis suggested that HPV infection is associated with increasing risk of PCa, which indicated a potential pathogenetic link between HPV and PCa.

show abstract

Section: Resultsmentioning

confidence: 99%

Association between human papillomavirus and prostate cancer: A meta-analysis

et al. 2017

View full text Add to dashboard Cite

show abstract

“…High-risk HPV DNA has been found in some unconventional HPV cancers, such as breast, prostate, colorectal, and lung cancers, and a causative role has been implied (210)(211)(212)(213). Although known to be associated with human cancers, the potential role of high-risk HPV in the carcinogenic steps of these cancers is controversial.…”

Section: Future Challengesmentioning

confidence: 99%

Human Papillomavirus Laboratory Testing: the Changing Paradigm

2016

View full text Add to dashboard Cite

SUMMARYHigh-risk human papillomaviruses (HPVs) cause essentially all cervical cancers, most anal and oropharyngeal cancers, and some vaginal, vulvar, and penile cancers. Improved understanding of the pathogenesis of infection and the availability of newer tests are changing the approach to screening and diagnosis. Molecular tests to detect DNA from the most common high-risk HPVs are FDA approved for use in conjunction with cytology in cervical cancer screening programs. More-specific tests that detect RNA from high-risk HPV types are now also available. The use of molecular tests as the primary screening tests is being adopted in some areas. Genotyping to identify HPV16 and -18 has a recommended role in triaging patients for colposcopy who are high-risk HPV positive but have normal cytology. There are currently no recommended screening methods for anal, vulvar, vaginal, penile, or oropharyngeal HPV infections. HPV testing has limited utility in patients at high risk for anal cancer, but p16 immunohistochemistry is recommended to clarify lesions in tissue biopsy specimens that show moderate dysplasia or precancer mimics. HPV testing is recommended for oropharyngeal squamous cell tumors as a prognostic indicator. Ongoing research will help to improve the content of future guidelines for screening and diagnostic testing.

show abstract

“…Epstein-Barr virus (EBV) is a ubiquitous herpes virus that is linked to multiple malignancies, including Burkitt’s lymphoma, Hodgkin’s disease, gastric cancer esophageal cancer cervical cancer and prostate cancer and nasopharyngeal carcinoma (NPC) [1-9]. Latent membrane protein 1 (LMP1) encoded by EBV functions as an essential factor in EBV-induced cell transformation and is expressed in many of the malignancies associated with EBV.…”

Section: Introductionmentioning

confidence: 99%

Epstein-Barr Virus encoded LMP1 regulates cyclin D1 promoter activity by nuclear EGFR and STAT3 in CNE1 cells

Shi

et al. 2013

J Exp Clin Cancer Res

View full text Add to dashboard Cite

The principal Epstein–Barr virus (EBV) oncoprotein, latent membrane protein 1 (LMP1) is strongly associated with nasopharyngeal carcinoma (NPC), a prevalent cancer in China. The epidermal growth factor receptor (EGFR) is important in carcinogenesis, as it is a ubiquitously expressed receptor tyrosine kinase. Signal transducer and activator of transcription 3 (STAT3) is a master transcriptional regulator in proliferation and apoptosis. Our previous study demonstrated that the nuclear EGFR could bind to the cyclin D1 promoter directly in the presence of LMP1, and the correlation between EGFR and STAT3 in NPC remains to be further explored. Here, we have shown that the interaction of EGFR and STAT3 increased in the nucleus in the presence of LMP1. LMP1 promoted both EGFR and STAT3 binding to the promoter region of cyclin D1, in turn, enhancing the promoter activity of cyclin D1. Furthermore, we demonstrated that both transcriptional activity and mRNA levels of cyclin D1 were decreased by small molecule interference of EGFR and STAT3 activity. These findings may provide a novel linkage between the EGFR and STAT3 signaling pathways and the activation of cyclin D1 by LMP1 in the carcinogenesis of NPC.

show abstract

Human papillomavirus and Epstein Barr virus in prostate cancer: Koilocytes indicate potential oncogenic influences of human papillomavirus in prostate cancer

Cited by 84 publications

References 16 publications

Association between human papillomavirus and prostate cancer: A meta-analysis

Association between human papillomavirus and prostate cancer: A meta-analysis

Human Papillomavirus Laboratory Testing: the Changing Paradigm

Epstein-Barr Virus encoded LMP1 regulates cyclin D1 promoter activity by nuclear EGFR and STAT3 in CNE1 cells

Contact Info

Product

Resources

About